9-benzyl-4-dimethylaminomethyl-6-methoxy-1,2,3,4-tetrahydrocarbazole | 59632-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-benzyl-4-dimethylaminomethyl-6-methoxy-1,2,3,4-tetrahydrocarbazole
• 英文别名: 4-dimethylaminomethyl-9-benzyl-6-methoxy-1,2,3,4-tetrahydrocarbazole；(9-Benzyl-6-methoxy-2,3,4,9-tetrahydro-1H-carbazol-4-ylmethyl)-dimethyl-amine；1-(9-benzyl-6-methoxy-1,2,3,4-tetrahydrocarbazol-4-yl)-N,N-dimethylmethanamine
• CAS: 59632-13-2
• 化学式: C₂₃H₂₈N₂O
• 分子量: 348.488
• InChiKey: RLXHAWJOGOMQQU-UHFFFAOYSA-N

物化性质

• 沸点：
  519.3±50.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  17.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE<br/>[FR] DERIVES HETEROARYLE ET ARYLE FUSIONNE ET METHODES D'UTILISATION ASSOCIEES
  申请人：WYETH CORP

  公开号：WO2005037283A1

  公开（公告）日：2005-04-28

  The present invention is directed to fused-aryl and heteroaryl derivatives of formula I, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibrornyalgia, pain, diabetic neuropathy, and combinations thereof. FORMULA

  本发明涉及公式I的融合芳基和杂环芳基衍生物，含有这些衍生物的组合物，以及它们用于预防和治疗由单胺再摄取改善的病症的方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病等，尤其是从包括重性抑郁障碍、血管运动症状、压力和急迫性尿失禁、纤维肌痛综合征、疼痛、糖尿病神经病变等在内的一组病症中选择的那些病症。
• Selective 5-HT 6 receptor ligands
  申请人：VIRGINIA COMMONWEALTH UNIVERSITY

  公开号：EP1693366A1

  公开（公告）日：2006-08-23

  Compounds which have enhanced affinity and selectivity for 5-HT6 receptors have been identified. These compounds can be used therapeutically in the treatment of mental disorders via administration in a pharmacologically acceptable delivery route to a patient in need thereof, or can be used to identify antagonists of 5-HT6 receptors by well known screening methodologies which could themselves be used in the treatment of mental disorders.

  已鉴定出对 5-HT6 受体具有更强亲和力和选择性的化合物。这些化合物可以通过药理学上可接受的给药途径用于治疗精神障碍，也可以通过众所周知的筛选方法确定 5-HT6 受体的拮抗剂，这些拮抗剂本身也可用于治疗精神障碍。
• Selective 5-HT6 receptor ligands
  申请人：——

  公开号：US20020103382A1

  公开（公告）日：2002-08-01

  Compounds which have enhanced affinity and selectivity for 5-HT 6 receptors have been identified. These compounds can be used therapeutically in the treatment of mental disorders via administration in a pharmacologically acceptable delivery route to a patient in need thereof, or can be used to identify antagonists of 5-HT 6 receptors by well known screening methodologies which could themselves be used in the treatment of mental disorders.

  对 5-HT 6 受体亲和力和选择性增强的化合物。这些化合物可以通过药理学上可接受的给药途径给有需要的病人服用，用于治疗精神障碍，也可以用于鉴定 5-HT 6 受体的拮抗剂。 6 受体的拮抗剂，这些拮抗剂本身也可用于治疗精神障碍。
• N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
  申请人：——

  公开号：US20040132800A1

  公开（公告）日：2004-07-08

  The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor. 1

  本发明提供的式 (I) 化合物是 5-HT 6 受体的拮抗剂。
• EP1149078A4
  申请人：——

  公开号：EP1149078A4

  公开（公告）日：2003-01-29